{
    "query_details": {
        "Age": "50",
        "Gender": "Female",
        "Medical Condition": "Triple-Negative Breast Cancer",
        "Location": "Indianapolis, IN",
        "Latitude": "39.7684",
        "Longitude": "-86.1581",
        "Distance": "100"
    },
    "stats": {
        "number_of_trials": 9,
        "trial_names": [
            "A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression",
            "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors",
            "Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers",
            "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",
            "A Study of SGN-B7H4V in Advanced Solid Tumors",
            "Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer",
            "Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab",
            "A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer",
            "Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)"
        ],
        "nct_numbers": "NCT05325866,NCT03821935,NCT05846789,NCT04225117,NCT05194072,NCT04849364,NCT05812807,NCT05902988,NCT05633654"
    }
}
